The Japanese Herbal (Kampo) Medicine Hochuekkito Attenuates Lung Inflammation in Lung Emphysema
-
- Isago Hideaki
- Department of Clinical Laboratory Medicine, Graduate School of Medicine, The University of Tokyo Hospital Department of Respiratory Medicine, Graduate School of Medicine, the University of Tokyo
-
- Mitani Akihisa
- Department of Respiratory Medicine, Graduate School of Medicine, the University of Tokyo
-
- Kohno Shiho
- Department of Respiratory Medicine, Graduate School of Medicine, the University of Tokyo
-
- Nagoshi Saki
- Department of Respiratory Medicine, Graduate School of Medicine, the University of Tokyo
-
- Ishimori Taro
- Department of Respiratory Medicine, Graduate School of Medicine, the University of Tokyo
-
- Saito Minako
- Department of Respiratory Medicine, Graduate School of Medicine, the University of Tokyo
-
- Tamiya Hiroyuki
- Department of Respiratory Medicine, Graduate School of Medicine, the University of Tokyo
-
- Miyashita Naoya
- Department of Respiratory Medicine, Graduate School of Medicine, the University of Tokyo
-
- Ishii Takashi
- Department of Respiratory Medicine, Graduate School of Medicine, the University of Tokyo
-
- Matsuzaki Hirotaka
- Department of Respiratory Medicine, Graduate School of Medicine, the University of Tokyo
-
- Yatomi Yutaka
- Department of Clinical Laboratory Medicine, Graduate School of Medicine, The University of Tokyo Hospital
-
- Nagase Takahide
- Department of Respiratory Medicine, Graduate School of Medicine, the University of Tokyo
-
- Jo Taisuke
- Department of Health Services Research, Graduate School of Medicine, the University of Tokyo
Search this article
Abstract
<p>Chronic obstructive pulmonary disease (COPD) is a systemic inflammatory disorder. It often causes weight loss, which is considered a poor prognostic factor. A Japanese herbal Kampo medicine, Hochuekkito (TJ-41), has been reported to prevent systemic inflammation and weight loss in COPD patients, but the underlying biological mechanisms remain unknown. In the present study, we investigated the role of TJ-41 in vivo using a mouse model of lung emphysema. We used lung epithelium-specific Taz conditional knockout mice (Taz CKO mice) as the lung emphysema model mimicking the chronic pulmonary inflammation in COPD. Acute inflammation was induced by intratracheal lipopolysaccharide administration, simulating COPD exacerbation. Mice were fed a diet containing 2% TJ-41 or a control diet. Taz CKO mice showed increased numbers of inflammatory cells in the bronchoalveolar lavage fluid compared to control mice. This effect was reduced by TJ-41 treatment. In the acute exacerbation model, TJ-41 mitigated the increased numbers of inflammatory cells in the bronchoalveolar lavage fluid and attenuated lung inflammation in histopathological studies. Additional in vitro experiments using the human macrophage cell line U-937 demonstrated that lipopolysaccharide-induced tumor necrosis factor-alpha expression was significantly downregulated by TJ-41. These results suggest that TJ-41 has anti-inflammatory effects in lung emphysema both in the chronic phase and during an acute exacerbation. In conclusion, our study sheds light on the anti-inflammatory effects of TJ-41 in lung emphysema. This establishes its potential as a new anti-inflammatory therapy and a preventive medicine for exacerbations during the long-time maintenance of COPD patients.</p>
Journal
-
- Biological and Pharmaceutical Bulletin
-
Biological and Pharmaceutical Bulletin 44 (1), 39-45, 2021-01-01
The Pharmaceutical Society of Japan
- Tweet
Keywords
Details 詳細情報について
-
- CRID
- 1391975831225371648
-
- NII Article ID
- 130007965315
-
- NII Book ID
- AA10885497
-
- ISSN
- 13475215
- 09186158
-
- NDL BIB ID
- 031209896
-
- PubMed
- 33390548
-
- Text Lang
- en
-
- Data Source
-
- JaLC
- NDL
- Crossref
- PubMed
- CiNii Articles
- KAKEN
-
- Abstract License Flag
- Disallowed